TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06480552: A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Loca

Sponsor: Teva Branded Pharmaceutical Products R&D LLC · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 240 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06480552 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06480552 Rescue Dossier →